This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Stryker (SYK) Stock Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
PacBio (PACB) Gets New Order for Revio System From Bioscientia
by Zacks Equity Research
PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.
Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Stock
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Here's Why You Should Retain Molina (MOH) in Your Portfolio
by Zacks Equity Research
Numerous contract wins, financial flexibility and strong performing Medicaid and Medicare segments poise Molina (MOH) well for growth.
Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View
by Zacks Equity Research
Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Acadia Healthcare (ACHC) Expands With New Hospital in Michigan
by Zacks Equity Research
Acadia Healthcare's (ACHC) partnership with Bronson Healthcare to expand its footprint in Michigan with Bronson Behavioral Health Hospital.
Are Medical Stocks Lagging Alcon (ALC) This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Here's Why You Should Retain Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.
Humana (HUM) Wins Contract to Serve Oklahoma's Medicaid Members
by Zacks Equity Research
Humana (HUM) secures a contract from the OHCA and is likely to provide improved health outcomes for Medicaid members of Oklahoma.
Centene (CNC) to Provide Managed Care for SoonerSelect Program
by Zacks Equity Research
Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
by Zacks Equity Research
For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.
Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up
by Zacks Equity Research
Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.
ALC or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALC vs. EW: Which Stock Is the Better Value Option?
Philips (PHG) Drives Healthcare Prospects With Enhanced Dataset
by Zacks Equity Research
Philips (PHG) announces its expansion with MIT IMES, which will help researchers and educators access a new critical care dataset.
ALC vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALC vs. IDXX: Which Stock Is the Better Value Option?
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
What Makes Alcon (ALC) a New Buy Stock
by Zacks Equity Research
Alcon (ALC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.
Philips (PHG) Drives Health Care Prospects With New Solutions
by Zacks Equity Research
Philips (PHG) announces Philips Virtual Care Management solutions, which provide a comprehensive approach to telehealth for patients, providers and payers.